AxoGen (NASDAQ:AXGN – Get Free Report) had its price objective increased by investment analysts at Canaccord Genuity Group from $18.00 to $22.00 in a research report issued on Monday,Benzinga reports.

“We are pleased to welcome Jesse to the Axogen team," said Michael Dale, Chief Executive Officer, and Director, Axogen. "His extensive experience in regulatory strategy and deep understanding of the ...

About Axogen Axogen (AXGN ... without the comorbidities associated with a second surgical site; Axoguard Nerve Connector®, a porcine submucosa ECM coaptation aid for tensionless repair of ...

Axogen, Inc. has announced the appointment ... the comorbidities associated with a second surgical site; Axoguard Nerve Connector , a porcine submucosa ECM coaptation aid for tensionless repair ...

Axogen (AXGN) is the leading Company focused ... the comorbidities associated with a second surgical site; Axoguard Nerve Connector®, a porcine submucosa ECM coaptation aid for tensionless ...

ALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, ...

Jan. 10, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary ...

Jan. 10, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the ...